Tests NoNO-42 in adults with acute ischemic stroke before clot treatment
Tests the drug NoNO-42 in adults having an acute ischemic stroke within 4.5 hours.
Plain-language title generated from the registry record
Registry title: NoNO-42 Trial in Acute Ischemic Stroke Patients Selected for Thrombolysis With or Without Endovascular Thrombectomy
Key facts
- Where
- Calgary, Edmonton, Hamilton, Ottawa, Saskatoon, Toronto, Vancouver, and Winnipeg, CanadaSee the 9 sites
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 90 years old?
Source: NCT06403267, who can take part
Where in Canada
- University of Calgary- Foothills Medical CentreCalgary, CanadaTaking people
- University of Alberta HospitalEdmonton, CanadaTaking people
- Hamilton General HospitalHamilton, CanadaTaking people
- Ottawa Hospital Research InstituteOttawa, CanadaTaking people
- Royal University HospitalSaskatoon, CanadaTaking people
- Sunnybrook Health Sciences CentreToronto, CanadaTaking people
- Unity Health Toronto, St. Michael's HospitalToronto, CanadaTaking people
- Vancouver General HospitalVancouver, CanadaTaking people
- University of ManitobaWinnipeg, CanadaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- NoNO Inc.
- Trial code
- NCT06403267
- Record updated
- 15 July 2025
- Original description
ACT-42 is a domain of the ACT-GLOBAL platform (NCT06352632).Read full original descriptionShow less
A Multicentre, Prospective, Randomized, Open Label, Blinded-Endpoint, Placebo-controlled, Single-dose Trial to Determine the Efficacy and Safety of NoNO-42 in Participants With Acute Ischemic Stroke Selected for Thrombolysis With or Without Endovascular Thrombectomy (ACT-42 Trial)
ACT-42 is a domain of the ACT-GLOBAL platform (NCT06352632).
This trial is a Phase 2b, multicenter, prospective, randomized, open label, blinded-endpoint (PROBE) controlled single-dose adaptive trial.
A total of up to 600 male and female participants aged ≥ 18 to ≤ 90 years harboring an acute ischemic stroke who are eligible for an intravenous thrombolytic with or without endovascular thrombectomy therapy will be enrolled within 4.5 hours of stroke onset/last known well.
Inclusion: Confirmed or suspected acute ischemic stroke (AIS) selected for intravenous thrombolysis; Onset (last-known-well) time to randomization time within 4.5 hours; Ages ≥ 18 to ≤ 90 years; Disabling stroke defined as a baseline National Institutes of Health Stroke Score (NIHSS) >5; Confirmed or suspected symptomatic anterior circulation intracranial occlusion. Tandem extracranial carotid and intracranial occlusions are permitted; Pre-stroke independent functional status in activities of daily living as judged by the enrolling physician. Patient must be living without requiring nursing care; Consent process completed as per national laws and regulation and the applicable ethics committee requirements.
Exclusion: Unlikely to initiate study drug administration before arterial puncture in those selected for EVT; Known prior receipt of NoNO-42 for any reason, including prior enrolment in this trial; Long term care facility resident or prisoner 10) Participation in another clinical trial outside of the ACT-GLOBAL platform investigating a drug or medical device or a neuro-interventional or surgical procedure that is not considered as standard care in the 30 days preceding trial enrolment; Any intracranial hemorrhage on qualifying imaging; Severe comorbid illness with life expectancy less than 90 days, or likely to prevent completing 90-day follow-up; Large extent early ischemic changes/infarct in the ischemic territory on qualifying imaging; Known/suspected pregnancy and/or lactation; Systolic blood pressure < 90 mmHg.